🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Genmab A/S (CPH:GMAB)
Denmark flag Denmark · Delayed Price · Currency is DKK
3,497.00
+1.00 (0.03%)
Nov 19, 2026, 5:00 PM CET
← View all transcripts

Jefferies Global Healthcare Conference

Nov 19, 2026

Summary

Phase III results for EPKINLY, Rina-S and petosemtamab supported plans for filings, data presentations and potential launches in 2027. Investment remains focused on the three assets, alongside growth and leverage commitments.

Ben Jackson
Analyst, Jefferies

Welcome all to the final day of Jefferies Global Healthcare conference in 2026. My name is Ben Jackson. I am one of the— joined by the Genmab team. We have Jan, Judith, Anthony, all on stage here. Obviously a very busy period for you in the last quarter, or even a very intense period during October. You have been asked a couple of times this question in the past, but I am going to open up with, based off what you saw in that month, was there anything that particularly surprised you guys in the team, or was it all as you had hoped and as you had analyzed and expected?

Jan van de Winkel
President and CEO, Genmab

I mean, overall, no big surprises. I mean, we had three late-stage products reading out in the phase III trials, with data which was unprecedented data. That was actually for each of these molecules following very much the phase II data. That is what we always said. I mean, usually with an antibody-based therapeutic, when you have very strong phase II data, that translates really well to the phase III data. So that happens for EPKINLY, for Rina-S, and for petosemtamab. What did surprise us, of course, the extent.

I mean, we hit the overall survival, and with a very, very impressive magnitude for both Rina-S and petosemtamab. And the magnitude was, I think, very impressive, and you cannot predict that, basically, based on the phase II data. But apart from that, I think the drugs are behaving as predicted and doing really, really well, and now it is basically getting them ready to bring them to the markets. So very busy, I can assure you, with getting all the paperwork done, all the regulatory interactions on the schedule, and then move them towards the market, hopefully next year. And so we think they are going to be very, very impactful drugs for the different settings.

For head and neck cancer, basically unprecedented data in the frontline setting, and that data will be presented hopefully pretty soon at a medical conference. For EPKINLY, we hope that that data will be presented even sooner. For diffuse large B-cell lymphoma, that is combining the standard of care in the community healthcare setting, R-CHOP, with EPKINLY, which is a two-second subcutaneous injection with no hospitalization required. So we think it is a perfect drug to really get accepted by the medical community very quickly in the frontline setting, which is half of the targetable market and t hen Rina-S, the data in ovarian cancer are very, very good.

Yes, there is competition coming up, but they should be like one and a half years behind us. It is all coming down to execution, and we have showed you that we are really, really good not only at spotting these molecules, which we did well, I think, for Rina and for peto, but also in execution. I mean, in less than two and a half years after we brought in Rina-S as a small phase I/II product in an early-stage trial by ProfoundBio, we now have six phase IIIs ongoing, announced or ongoing, and more to come, I can tell you, for Rina. The first one already reading out with unprecedented data. I think we are in good shape to create a good market.

We describe these markets as basically $3 billion+ , larger than $3 billion for EPKINLY, larger than $2 billion for Rina-S, and multi-billion dollars. We think that actually peto will be our biggest product in the coming years. You can fill in your favorite number, I think, yourself. We want to actually do that on the basis of data and visibility in phase III trials. We are in very good shape to build the company to the next level. We could not be more excited, and we are delighted to be here with all of you in wonderful London. It is not raining today, so the sun is shining, and we hope to create some extra sunshine here in the room with this interaction.

Ben Jackson
Analyst, Jefferies

It is perhaps right to say it is not raining yet in London. We should not get ahead of ourselves. I guess looking forward into 2027, what is it that you see as the key milestones for Genmab going into the next 12 months?

Jan van de Winkel
President and CEO, Genmab

I mean, key milestones, clearly second-line head and neck data, phase III data for petosemtamab in Q1, for sure. Then it is about regulatory filings accepted for Rina-S and peto and epcoritamab, basically. Then also the primary datasets being presented. I mean, in the next 12 months, we hope to present the EPKINLY data quite quickly at the medical conference and w e will give you an update once we know more about the exact conference which we can target there. The same holds for petosemtamab and Rina-S.

So datasets, and then, of course, the most important is launches for these three, hopefully, medicines at that time after being dealt with by the regulators and getting a positive recommendation. I think launches are really important, so we are very much focusing on further building our commercial team, getting all the manufacturing supply chains in good shape and order to actually provide the market, because we actually get a lot of requests, not only me, but also the whole executive team, by other companies, basically to actually ask us to combine their new medicine or candidate medicine with our medicines like Rina-S and petosemtamab.

They are seen as the absolute winners, for sure frontrunners in the different categories, b ut also we get more and more requests from patients who really want to get access to these medicines already before they actually are going to be approved on the market. So we are also working on programs to actually make them available to help patients in a more proactive phase. So I think a lot of key catalysts in the coming year, and I haven't even mentioned the earlier clinical pipeline.

We're also building a very strong early clinical pipeline. We deliberately haven't spoken about that because we didn't want to confuse the market, but we have been blessed with a very good track record in the past. There's right now eight medicines on the market based on our science or technology. Soon there will be nine in the U.S. I mean, Frehemgo from Novo Nordisk was recently approved in Europe based on our bispecific technology for hemophilia. So that will definitely be the ninth program and t hen hopefully next year we will move it up to 11 when peto and Rina are approved as medicines. That is in the end why we do all of this work with the team, to actually bring better medicines to patients and help them in a very impactful way. I think we're well on track here.

Ben Jackson
Analyst, Jefferies

Certainly. Maybe we'll touch on petosemtamab first, given the recency of it as well. Look, the 50% reduction in risk of death at the first interim, certainly very impressive from our side. Could you speak perhaps to the level of confidence you have around that dataset? Is there much you can say at this point about the balance between the subgroups of patients that people typically focus on too?

Jan van de Winkel
President and CEO, Genmab

I should probably ask Judith to give you a bit of color there, so Head of Development, and then see what I can add in there.

Ben Jackson
Analyst, Jefferies

Of course.

Judith Klimovsky
Chief Development Officer, Genmab

Yeah. As you alluded, it has a hazard ratio of 0.50 in overall survival. It's not something that you see every day. And to give context, the prior two drugs approved in head and neck was one in 2008, cetuximab, with a hazard ratio of 0.8. For overall survival, at that time, was transformative and increased the overall survival from 7.5- 10 months. The next milestone came in 2018 with pembro. There, the overall survival was 0.75, 0.70, depending pembro. The overall survival went from 10 months to 12- 13.

And here, w ith the top-line results that we communicated, peto-pembro compared with pembro, standard of care, has a hazard ratio of 0.50. So these results, plus the other co-primary overall response rate with an odds ratio of 0.17, put this dataset as once in a lifetime for this particular disease. We always communicated that the results are in the intention-to-treat population, which is the population. Of course, we did many subgroup analyses, and all trend in the same direction, which is every patient derived benefits.

Jan van de Winkel
President and CEO, Genmab

Good.

Judith Klimovsky
Chief Development Officer, Genmab

And we will communicate as Jan alluded, one of the milestone is to communicate, because we communicated only the top line, which are the primary. We need to communicate all the secondary efficacy endpoints, which are so meaningful. PFS, time to respond, duration of response, and of course, safety. This will unleash the full potential of peto and the transformative nature of the data.

Jan van de Winkel
President and CEO, Genmab

Let me add a bit more color, Judith, on that. I said already at the investor call the end of October, when we actually reviewed that dataset, what actually struck me very, very impressively was that the lead oncologist from Genmab was describing in the portfolio Board meeting, which I was chairing that afternoon, just before you saw the press release, she was describing the benefit in all of the subgroups. At some point, I looked into her face, and I saw there were tears running from both of her eyes, basically over her face, because she had never, ever in her whole career seen data like this for any other product.

So the data is going to be really, really impressive, and that is in the end where it's really meaningful. I think we're going to create a big difference for patients there, not only in the frontline setting, but also in other settings. We are going to move very quickly to the locally advanced head and neck cancer setting, which is even bigger. And why are we doing that? Because we think that this drug will actually work well with pembrolizumab in the earlier setting, even better than in the frontline setting and t hat is a setting where you can actually cure patients, which is not always necessarily possible in the frontline and second-line metastatic areas.

So then because we want to make the biggest possible impact on patients' lives, and that is where we can do it. That will not be all. You will see a number of new phase III's being announced pretty soon. So k eep the cards close to our chest because of competition. We can talk about that, of course, also in this session. But we think that peto is in a separate category. It's in a unique category, and that will be very, very clear once you see more of the data. I should probably keep it with that.

Ben Jackson
Analyst, Jefferies

I mean, on the competition point, I guess one of the questions that you must get asked quite frequently is the strategy to go without chemo in that frontline setting. Perhaps you could talk to us about the percentage of patients today that get a chemo-free option, where you think that potentially will go after you've had this fairly transformative data, and what the rationale was to go without chemotherapy in that frontline.

Jan van de Winkel
President and CEO, Genmab

Judith?

Judith Klimovsky
Chief Development Officer, Genmab

So I can expand what compelled us to go with pembro, or just to support the strategy that is set up by former Merus, was the data. So b asically, the chemo backbone using head and neck is carbo 5-FU. It is not an easy chemo backbone. 5-FU, it is four days infusion IV, and it is pretty toxic. So when we saw the data of the combo, peto-pembro, basically you achieved a higher reduction of tumor burden with a much more milder safety profile in an unprecedented fashion.

So this is why today, it is not clear how many patients use pembro versus pembro chemo. It is a multidimensional decision. But from published data, it is 2:1 two pembro alone, one for one pembro chemo, based on CPS, tumor burden, frailty, and comorbidities. But with this data, it is creating a transform, a new reality for the patient and an option that did not exist before.

Ben Jackson
Analyst, Jefferies

And then if we think about the locally advanced setting as well, in terms of patient numbers, it represents a similar amount to the metastatic setting.

Judith Klimovsky
Chief Development Officer, Genmab

Yes and no.

Ben Jackson
Analyst, Jefferies

They are all thereabouts.

Judith Klimovsky
Chief Development Officer, Genmab

Yes. When head and neck is diagnosed, 60% is diagnosed as locally advanced. From those 60%, and this is why Jan said, "There you can cure.

Ben Jackson
Analyst, Jefferies

Yeah.

Judith Klimovsky
Chief Development Officer, Genmab

Unfortunately, only 40%-50% of patients will be cured. 60% will recur.

Ben Jackson
Analyst, Jefferies

Yeah.

Judith Klimovsky
Chief Development Officer, Genmab

And will recur within two years and t his is the population that we explore in the phase III. But for locally advanced, you can really transform—

Ben Jackson
Analyst, Jefferies

Yeah.

Judith Klimovsky
Chief Development Officer, Genmab

—because you go earlier, you can cure.

Ben Jackson
Analyst, Jefferies

Yeah. I guess to build on that thinking commercially, is this something that could show a fixed dose duration? Do we know, or is it something that you treat to progression so the follow-up could be significantly longer?

Judith Klimovsky
Chief Development Officer, Genmab

So usually in the locally advanced, you don't treat till progression because you cure.

So you treat for a maximum amount of cycles.

Ben Jackson
Analyst, Jefferies

Yeah.

Judith Klimovsky
Chief Development Officer, Genmab

Until you believe that you induce and you consolidate, but it's not till progression because the tumor doesn't exist.

Ben Jackson
Analyst, Jefferies

Yeah. And then on the colorectal side as well, so recently announced a few trials there. We've seen the phase II data updates recently. Perhaps you could talk to the level of confidence you have going into that setting with peto specifically.

Judith Klimovsky
Chief Development Officer, Genmab

We are very confident. So what Jan said is, I want to reinforce that. We acquired Rina-S with 39 patients. Based on the data, we moved from first in human, first patient in January 2023, to first patient in the phase III in January 2025.

Ben Jackson
Analyst, Jefferies

Yeah.

Judith Klimovsky
Chief Development Officer, Genmab

So if something that we have shown is that we are good at interpreting data and making the right decisions.

Ben Jackson
Analyst, Jefferies

For sure. The Rina-S side then, if we move on to there, certainly again, some pretty impressive data in that ovarian cancer setting. Perhaps you can talk to the level of confidence you have across those subgroups that we look at in terms of folate receptor alpha progression. It is obviously a debate, and I think you know the question was going to come.

Jan van de Winkel
President and CEO, Genmab

Yes.

Judith Klimovsky
Chief Development Officer, Genmab

We have a range for PFS of 0.33 or 0.29—

Ben Jackson
Analyst, Jefferies

Yeah.

Judith Klimovsky
Chief Development Officer, Genmab

—and 044 or 043. You can envision the forest plot, so across the board.

Ben Jackson
Analyst, Jefferies

Okay. Of course. Perhaps also you could speak to the tolerability profile of Rina-S. I think that's an important consideration we have to think about too.

Judith Klimovsky
Chief Development Officer, Genmab

Yeah. And thank you for the question. So as we put in the press release, the safety is consistent with the known safety profile of Rina-S, and we presented at IGCS data on 102 patients for part C. So basically, the main safety is myelosuppression with no safety signal related to neuropathy, stomatitis, ocular, or ILD.

Ben Jackson
Analyst, Jefferies

And do we know why that is? Because it's obviously with the payload, it's something that we would potentially expect. So have we got good reasonings behind it?

Jan van de Winkel
President and CEO, Genmab

I mean, we have definitely candidates there. I think it's a unique combination of this antibody with this linker and payload. This is a very hydrophilic linker. This allows you to attach multiple hydrophobic payloads to an antibody molecule without basically impacting the PK/PD of that molecule, and that is absolutely unique. We think that it's the combination of the payload with the linker, with this antibody, which makes this unique and also prevents the antibody from interacting with Fc receptors, which can cause ILD for other ADCs.

So I think it's a unique combination. What I want to say here is this year in the early clinical setting, we moved two more ADCs into the clinic based on a Genmab antibody and a linker payload combination from legacy ProfoundBio. We will actually file another IND very, very soon in the coming months on a new ADC also using a Genmab antibody and then the same linker payload combination from legacy ProfoundBio, with sensational preclinical data. We don't know yet what the clinical profile will look like, but I think it's a combination here.

And it's very difficult to predict that. What we did learn already years ago when we were working together with Seattle Genetics on TIVDAK. It was called tisotumab vedotin at that time. We tested four different linkers, four different payloads. For whatever reason, this MMAE cleavable, protease cleavable linker was the perfect one for tissue factor, as a rapidly internalizing molecule for TIVDAK. But you have to actually empirically test that, and it's actually not really clear what the exact dynamics are. But here, I think the combination is really, really good.

We believe we have a unique molecule with a very attractive safety profile and a very, very good efficacy profile, much better than some of the competitors. Also, when you look at some of the competitors for Rina-S, which should be like one and a half years behind us for sure, they have a lot more safety issues and challenges. I heard that one of them forgot to put the ILDs on the poster at ESMO. After being reminded in the room by a doctor, she said, "Well, oh, it's only 9% ILD." Draw your conclusions yourself.

Ben Jackson
Analyst, Jefferies

Yes. So we've seen this data now for the platinum-resistant ovarian cancer. To what extent for you does this de-risk us thinking about the endometrial space as well? Because the data's a little bit different in terms of the competition there too. So how much do you take from it?

Judith Klimovsky
Chief Development Officer, Genmab

Yeah, so we saw the data from endometrial, the first phase III. We believe that Rina has a superior and differentiated profile. In terms of safety, we discussed with no stomatitis or ocular, which others have. We put the phase III on place, which is actively recruiting.

Ben Jackson
Analyst, Jefferies

Yeah.

Judith Klimovsky
Chief Development Officer, Genmab

So we expect this result will provide a magnitude of benefit with the safety and convenience, because Rina is every three weeks versus others that are every two weeks.

Ben Jackson
Analyst, Jefferies

Yeah.

Judith Klimovsky
Chief Development Officer, Genmab

That will make a good value proposition and target product profile for patients, even it won't be first.

Ben Jackson
Analyst, Jefferies

Yeah.

Judith Klimovsky
Chief Development Officer, Genmab

It will be best.

Ben Jackson
Analyst, Jefferies

Of course. And then the third of the triad of October, I guess, comes down to EPKINLY. So we saw that frontline data, again, impressive. What is it that you would encourage us to have a look at in detailed data when it eventually comes? Obviously, not too sure yet.

Judith Klimovsky
Chief Development Officer, Genmab

Yeah. And I could say that given the others that are approved in combination to R-CHOP or R-CHP—

Ben Jackson
Analyst, Jefferies

Yeah.

Judith Klimovsky
Chief Development Officer, Genmab

—the subgroups will be important, as we already communicated, has a hazard ratio of 0.49 in the three to five and in the two to five. Of course, there are very important subgroups that other first line failed to benefit. So this will be important. And again, the whole value proposition in terms of efficacy, safety, and convenience.

Ben Jackson
Analyst, Jefferies

Yeah. Got it. Then the other consideration, I guess, is you have a competitor running with a POLIVY backbone as well. You get asked often, what do you think ultimately ends up being the positioning for those two assets based on those potential profiles? Is it of interest to Genmab to run something similar too?

Judith Klimovsky
Chief Development Officer, Genmab

Yeah. So we said it recurrently, our job is the standard of care, our job is the standard of care, and our job is the standard of care. Now, adding epcoritamab, EPKINLY, which is a subcutaneous weekly for three months and then once every three weeks, is a very good value with this efficacy benefit for the community and even for academic centers because the data is so compelling.

Ben Jackson
Analyst, Jefferies

Yeah.

Judith Klimovsky
Chief Development Officer, Genmab

So we believe that this is the standard. We have 37 patients treated with Epco-Pola-CHP, and the abstract is in the public domain. We will present this data at ASH, b ut we believe that R-CHOP is the standard of care, and R-CHOP, EPKINLY will become the new standard of care.

Ben Jackson
Analyst, Jefferies

Very clear. Anthony, I will bring you in here because you have been patiently waiting on the end. Look, you have given some pretty clear thoughts in and around OpEx and where investment goes. Could you perhaps remind us thinking about how we should think about that investment period now that you have had the detailed data here?

Anthony Pagano
CFO, Genmab

Yeah, sure. Thanks, Ben. So maybe two things to start. Our investment priorities are clear and unchanged, and the same goes for our financial commitments, clear and unchanged. In terms of our investment priorities, they are probably pretty obvious, but let me remind you, it is investing fully behind EPKINLY, Rina-S, and petosemtamab to unlock the full value there, both from a development and a commercial perspective. In terms of our financial commitments, maybe to direct the questions towards the 2027 commentary I provided on our Q3 call, what I said there is that 2027 OpEx is in a reasonable place when we look at Bloomberg and FactSet, and that remains true here today.

As that translates though to our financial commitments, when we acquired Merus in Q4 of last year, we outlined our financial commitments as part of that acquisition. Number one was to maintain strong profitability during the course of 2026. Here, through Q3, we're up 9%. The second commitment we made was to have growth in 2027. I reaffirmed that commitment on Q3, and I reaffirmed that commitment today. Then third but not least, in terms of our balance sheet, we said that we would get below 3x gross leverage by the end of 2027, and again, reaffirming that commitment here today. So again, investment priorities are super clear, and our financial commitments are super clear, and we stand fully behind those.

Ben Jackson
Analyst, Jefferies

I guess the final question I have time for, when you reach that deleveraging aim, is potential BD and M&A back on the cards here, or are you pretty happy with what's in front of you?

Anthony Pagano
CFO, Genmab

Okay. Yeah, so I think if we think about this, first of all, to be clear, from a capital allocation perspective, here and now, it's about focus and execution, focus and execution. We're going to, again, invest through the P&L behind these three assets, and we're going to delever. Once we get beyond that, I think we'll look and evaluate where we're at, both from an organic and inorganic perspective. So that's really a conversation for a later day.

Ben Jackson
Analyst, Jefferies

For sure. Look, thank you so much, all three of you, for joining. Congratulations on the recent successes, and exciting to see where this goes from here. So thank you, and enjoy the rest of your day.